Enact Holdings Inc   (ACT)
Other Ticker:  
    Sector  Financial    Industry Insurance Brokerage
   Industry Insurance Brokerage
   Sector  Financial
Price: $31.4400 $0.36 1.158%
Day's High: $31.47 Week Perf: -0.29 %
Day's Low: $ 31.03 30 Day Perf: 4.8 %
Volume (M): 212 52 Wk High: $ 31.85
Volume (M$): $ 6,653 52 Wk Avg: $28.07
Open: $31.12 52 Wk Low: $24.00

 Market Capitalization (Millions $) 5,033
 Shares Outstanding (Millions) 160
 Employees -
 Revenues (TTM) (Millions $) 1,164
 Net Income (TTM) (Millions $) 651
 Cash Flow (TTM) (Millions $) -7
 Capital Exp. (TTM) (Millions $) 0

Enact Holdings Inc

Watson Pharmaceuticals, Inc. completed the acquisition of Actavis Group. “Actavis, Inc.” is a leading integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (“OTC”) pharmaceutical products.

Prescription pharmaceutical products in the U.S. generally are marketed as either generic or brand pharmaceuticals. Generic pharmaceutical products are bioequivalents of their respective brand products, or in cases of protein-based biologic therapies, biosimilar, and provide a cost-efficient alternative to brand products. Brand pharmaceutical products are marketed under brand names through programs that are designed to generate physician and consumer loyalty. Through our Anda Distribution Segment, we distribute pharmaceutical products, primarily generics, which have been commercialized by us and others, to pharmacies and physicians’ offices. As a result of the differences between the types of products we market and/or distribute and the methods we distribute these products, we operate and manage our business as three distinct operating segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. The Company also develops and out-licenses generic pharmaceutical products through its Medis third-party business.

We apply three key strategies to achieve growth for our Actavis Pharma and Actavis Specialty Brands pharmaceutical businesses: (i) internal development of differentiated and high-demand products, including, in certain circumstances, challenging patents associated with these products, (ii) establishment of strategic alliances and collaborations and (iii) acquisition of products and companies that complement our current business. We believe our three-pronged strategy will allow us to expand both our brand and generic product offerings globally. Our Medis third-party business has a broad portfolio of over 200 developed products for out licensing to approximately 300 customers, primarily in Europe. Our Anda Distribution business distributes products for over 260 suppliers and is focused on providing next-day delivery and responsive service to its customers. Our Anda Distribution business also distributes a number of generic and brand products in the U.S. Growth in our Anda Distribution business will be largely dependent upon FDA approval of new generic products in the U.S. and expansion of our base of suppliers.

In our Actavis Pharma and Actavis Specialty Brands operations, we sell our generic and brand pharmaceutical products primarily to drug wholesalers, retailers and distributors, including national retail drug and food store chains, hospitals, clinics, mail order, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. In our Anda Distribution business, we distribute generic and certain select brand pharmaceutical products to independent pharmacies, alternate care providers (hospitals, nursing homes and mail order pharmacies), pharmacy chains, physicians’ offices and buying groups.

The pharmaceutical industry is highly competitive. In our Actavis Pharma and Actavis Specialty Brands businesses, we compete with different companies depending upon product categories, and within each product category, upon dosage strengths and drug delivery systems. Such competitors include the major brand name and generic manufacturers of pharmaceutical products. In addition to product development, other competitive factors in the pharmaceutical industry include product quality and price, reputation and service and access to proprietary and technical information. It is possible that developments by others will make our products or technologies noncompetitive or obsolete.
Competing in the brand product business requires us to identify and bring to market new products embodying technological innovations. Successful marketing of brand products depends primarily on the ability to communicate their effectiveness, safety and value to healthcare professionals in private practice, group practices and receive formulary status from managed care organizations. We anticipate that our brand product offerings will support our existing areas of therapeutic focus. Based upon business conditions and other factors, we regularly reevaluate our business strategies and may from time to time reallocate our resources from one therapeutic area to another, withdraw from a therapeutic area or add an additional therapeutic area in order to maximize our overall growth opportunities. Our competitors in brand products include major brand name manufacturers of pharmaceuticals. Based on total assets, annual revenues and market capitalization, our Actavis Specialty Brands segment is considerably smaller than many of these competitors and other global competitors in the brand product area. Many of our competitors have been in business for a longer period of time, have a greater number of products on the market and have greater financial and other resources than we do. If we directly compete with them for certain contracted business, such as the Pharmacy Benefit Manager business, and for the same markets and/or products, their financial strength could prevent us from capturing a meaningful share of those markets.

   Company Address: 8325 Six Forks Road Raleigh 27615 NC
   Company Phone Number: 846-4100   Stock Exchange / Ticker: NASDAQ ACT
    Next quarterly dividend pay out on June 13, 2024.

Customers Net Income fell by ACT's Customers Net Profit Margin fell to

-28.06 %

3.1 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV   -2.88%    
ABT   -0.05%    
BMY   -4.01%    
JNJ   -0.51%    
MRK        0.17% 
PFE        2.35% 
• View Complete Report

Enact Holdings Inc

Enact Holdings Inc Sees Revenue Growth Despite Earnings Decline in Q1 2024

The recent financial results of Enact Holdings, Inc. paint a mixed picture for the company. On one hand, the company saw a 3.786% increase in revenue in the first quarter of 2024, reaching $291.58 million compared to $280.94 million in the same period last year. This growth outpaced that of its peers in the Insurance Brokerage sector, indicating a positive trend in the company's top-line performance.
However, on the earnings per share front, Enact Holdings, Inc. experienced a decline. Income per share dropped by -6.48% to $1.01, down from $1.08 in the prior year. This decrease in earnings could be a cause for concern for investors, as it reflects a decrease in profitability for the company.


Enact Enhances Shareholder Value with 16% Increase to Quarterly Dividend and New $250 Million Share Repurchase Program

Published Wed, May 1 2024 8:10 PM UTC

Enact Increases Quarterly Dividend by 16% and Announces $250 Million Share Repurchase Program
Enact Holdings, Inc. (Nasdaq: ACT), a leading provider of private mortgage insurance, has announced a 16% increase to its quarterly dividend and the initiation of a new $250 million share repurchase program. This move reflects the company's commitment to enhancing shareholder va...

Product Service News

Enact Holdings Defies Competitive Tensions, Collaborates with PMI Rate Pro - A Strategic Move Forward in the Mortgage Insurance Industry

Published Wed, Apr 3 2024 4:11 PM UTC

Continuing its streak as a frontrunner in the financial industry, Enact Holdings, Inc. (Nasdaq: ACT) (Enact) announced its seamless integration with PMI Rate Pro. Based in Raleigh, North Carolina, Enact, known for providing top-tier private mortgage insurance through its insurance subsidiaries, announced this collaboration on April 3, 2024. This feat would enhance the compan...

Enact Holdings Inc

Enact Holdings Inc. Sees Modest Revenue Growth in Fiscal Fourth Quarter of 2023

Enact Holdings Inc., a prominent player in the Insurance Brokerage industry, recently announced its financial results for the fiscal fourth quarter of 2023. While the company showcased solid performance in various aspects, it still lagged behind its industry counterparts in terms of top-line growth.
The company reported a 6.989% increase in revenue, from $276.84 million to $296.19 million, on a year-over-year basis. This steady growth is undoubtedly a positive sign, but it falls short of the 11.66% average growth achieved by other companies in the industry during the fourth quarter of 2022. Furthermore, revenue decreased by -0.951% from the previous period, demonstrating the need for Enact Holdings Inc. to further strengthen its top-line growth strategy.


Enact Holdings, Inc. Declares Quarterly Dividend: Fueling Investor Confidence and Driving Stock Performance

Published Tue, Feb 20 2024 9:15 PM UTC

Enact Holdings, Inc. Declares Quarterly Dividend: Positive Impact on Stock Performance
Enact Holdings, Inc. (Nasdaq: ACT) recently announced a quarterly dividend of $0.16 per common share, showcasing the company's strong financial position and commitment to rewarding shareholders. The dividend payout, scheduled for March 13, 2024, comes at a time when the company's stock...


Enact Holdings Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com